Safety Issues Clinical Trial
Official title:
Physician-initiated, Prospective, Multi-center, Observational Study: The Safety and Efficiency Result of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.
Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients over 18 years old. 2. acute or subacute limb ischemia patients with Rutherford classification stage range from I to IIb. 3. Patients with Rutherford classification range from 3 to 5. 4. The guide wire should pass through the lesion of femoropopliteal artery, and further endovascular treatment is performed. In this study, we did not limit the methods of the guide wire passing through the target lesion. After the angiography and/or performed under digital subtraction angiography(DSA) which confirmed the existing of thrombus, and which is related to occlusions of lower extremity or in-stent restenosis. 5. Pharmacomechanical thrombectomy (PMT) and/or catheter-directed thrombolysis (CDT) was or were used for thrombus removal. 6. The lower extremity artery needs to have a healthy runoff of no less than 10 cm above the ankle, and at least one healthy dorsalis pedis artery, medial or lateral plantar artery connected with the digital artery below the ankle. 7. Informed consent signed by patients. Exclusion Criteria: 1. acute or subacute limb ischemia patients with Rutherford classification stage III. 2. Patients with thromboangiitis obliterans. 3. Patients with failure of endovascular treatment, and transfer to open surgery or hybrid operation. 4. People with stroke, cerebral hemorrhage, gastrointestinal bleeding or myocardial infarction and so on in the past 3 months. 5. Patients with known allergy to heparin, low molecular weight heparin and contrast agents. 6. Patients with high bleeding risk. 7. Women during pregnancy and lactation. 8. Patients with other diseases that may lead to difficulties in the trial or significantly shorten the life expectancy (< 2 years), such as tumors, severe liver disease, cardiac insufficiency. 9. Patients who have been enrolled in other clinical trials in the past 3 months. 10. Patients who are unwilling or refuse to sign the informed consent form. - |
Country | Name | City | State |
---|---|---|---|
China | Fan xin | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
First People's Hospital of Hangzhou | Chengdu University of Traditional Chinese Medicine, First Affiliated Hospital of Zhejiang University, Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology, Qingdao haici hospital, RenJi Hospital, Second Affiliated Hospital of Suzhou University, Shanghai Zhongshan Hospital, Xuanwu Hospital, Beijing |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Amputation-free survival | The amputation-free survival after endovascular surgery | post-interventional 12months | |
Primary | Adverse events at post-interventional 1months | the incidence of amputation, operation-related distal embolism, rethrombosis, acute renal failure and/or death. | post-interventional 1 months | |
Secondary | Technical success rate | Technical success rate | Post operation up to 1 day | |
Secondary | Clinical-driven Target lesion reintervention(CD-TLR) rate | Clinical-driven Target lesion reintervention rate | post-interventional 1,3,6,12 months | |
Secondary | Clinical-driven Target vascular reintervention(CD-TVR) rate | Clinical-driven Target vascular reintervention rate | post-interventional 1,3,6,12 months | |
Secondary | The total time used in the operation | The total time used in the operation | Intraoperative | |
Secondary | Primary patency(PP)of the lesions | Primary patency(PP)of the lesions | post-interventional 1,3,6,12 months | |
Secondary | Changes of quality of life assessed by VascuQol scale | Changes of quality of life | post-interventional 1,3,6,12 months | |
Secondary | Direct medical expenses (2-year cumulative hospitalization expenses and endovascular expenses related to target lesions) | Direct medical expenses | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
Recruiting |
NCT05546567 -
NOPARK Open Label Extension Study
|
N/A | |
Recruiting |
NCT05413226 -
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
|
N/A | |
Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
Completed |
NCT04689035 -
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144
|
Phase 1 | |
Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
Completed |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
Enrolling by invitation |
NCT06446778 -
Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
|
||
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
Completed |
NCT04499482 -
Safety and Tolerability of Soy Fiber
|
N/A | |
Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
Not yet recruiting |
NCT04774900 -
Standardization of Ambulance Equipment
|